Molecular Pharmacology Branch (RB, EH), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.
Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Arch Biochem Biophys. 2022 Sep 30;727:109296. doi: 10.1016/j.abb.2022.109296. Epub 2022 May 17.
A tritiated derivative of the sponge-derived natural product spongistatin 1 was prepared, and its interactions with tubulin were examined. [H]Spongistatin 1 was found to bind rapidly to tubulin at a single site (the low specific activity of the [H]spongistatin 1, 0.75 Ci/mmol, prevented our defining an association rate), and the inability of spongistatin 1 to cause an aberrant assembly reaction was confirmed. Spongistatin 1 bound to tubulin very tightly, and we could detect no significant dissociation reaction from tubulin. The tubulin-[H]spongistatin 1 complex did dissociate in 8 M urea, so there was no evidence for covalent bond formation. Apparent K values were obtained by Scatchard analysis of binding data and by Hummel-Dreyer chromatography (3.5 and 1.1 μM, respectively). The effects of a large cohort of vinca domain drugs on the binding of [H]spongistatin 1 to tubulin were evaluated. Compounds that did not cause aberrant assembly reactions (halichondrin B, eribulin, maytansine, and rhizoxin) caused little inhibition of [H]spongistatin 1 binding. Little inhibition also occurred with the peptides dolastatin 15, its active pentapeptide derivative, vitilevuamide, or diazonamide A, nor with the vinca alkaloid vinblastine. Strong inhibition was observed with dolastatin 10, hemiasterlin, and cryptophycin 1, all of which cause aberrant assembly reactions that might actually mask the spongistatin 1 binding site. Spongistatin 5 was found to be a competitive inhibitor of [H]spongistatin 1 binding, with an apparent K of 2.2 μM. We propose that the strong picomolar cytotoxicity of spongistatin 1 probably derives from its extremely tight binding to tubulin.
一种海绵来源天然产物海绵抑素 1 的氚化衍生物被制备,并研究了其与微管蛋白的相互作用。[H]海绵抑素 1 被发现快速地在单一结合位([H]海绵抑素 1 的低比活度,0.75 Ci/mmol,阻止了我们确定其结合速率)与微管蛋白结合,并且海绵抑素 1 不能引起异常组装反应得到了证实。海绵抑素 1 与微管蛋白结合非常紧密,我们无法检测到从微管蛋白上的显著解离反应。微管蛋白-[H]海绵抑素 1 复合物在 8 M 尿素中解离,因此没有证据表明形成了共价键。通过 Scatchard 分析和 Hummel-Dreyer 色谱法(分别为 3.5 和 1.1 μM)获得表观 K 值。评价了大量长春花烷类药物对[H]海绵抑素 1 与微管蛋白结合的影响。未引起异常组装反应的化合物(海兔毒素 B、埃博霉素、美坦生和瑞霍霉素)对[H]海绵抑素 1 结合的抑制作用很小。类似地,多拉司他汀 15、其活性五肽衍生物、维替鲁胺或重氮胺 A 以及长春碱类长春碱也没有抑制作用。多拉司他汀 10、海兔毒素和 cryptophycin 1 则表现出强烈的抑制作用,它们都引起异常组装反应,可能实际上掩盖了海绵抑素 1 的结合位点。海绵抑素 5 被发现是[H]海绵抑素 1 结合的竞争性抑制剂,其表观 K 为 2.2 μM。我们提出,海绵抑素 1 具有强烈的皮摩尔细胞毒性,可能源于其与微管蛋白的极其紧密结合。